Comparison of pathologic stage in patients receiving esophagectomy with and without preoperative chemoradiation therapy for esophageal SCC

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 12, Issue 12, 2014, Pages 1697-1705

  Wang, Bing Yen ^a,b,c,d   Lin, Ping Yi ^d   Wu, Shiao Chi ^c   Chen, Hui Shan ^c   Hsu, Po Kuei ^c   Shih, Chih Shiun ^b   Liu, Chao Yu ^b,c,e   Liu, Chia Chuan ^b   Chen, Yao Li ^a,f  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b KOO FOUNDATION SUN YAT SEN CANCER CENTER   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^e FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^f KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PREOPERATIVE TREATMENT; RETROSPECTIVE STUDY; SURVIVAL TIME; TAIWAN; TREATMENT OUTCOME; TREATMENT RESPONSE; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TAIWAN;

EID: 84918825881     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2014.0171     Document Type: Article

References (27)

1. Lightdale CJ. Esophageal cancer. Am J Gastroenterol 1999; 94: 20-29.
2. Chen MF, Yang YH, Lai CH, et al. Outcome of patients with esophageal cancer: A nationwide analysis. Ann Surg Oncol 2013; 20: 3023-3030.
3. Ajani JA, D'Amico TA, Almhanna K, et al. NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers. Version 1.2014. Available at: NCCN.org. Accessed July 29, 2014.
4. Van Hagen P, Hulshof MC, Van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-2084.
5. Teoh AY, Chiu PW, Yeung WK, et al. Long-Term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: Results from a randomized controlled trial. Ann Oncol 2013; 24: 165-171.
6. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable esophageal carcinoma: An updated meta-Analysis. Lancet Oncol 2011; 12: 681-692.
7. Courrech Staal EF, Aleman BM, Boot H, et al. Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer. Br J Surg 2010; 97: 1482-1496.
8. Edge SB, Byrd DR, Compton CC, et al, eds. AJCC Cancer Staging Manual.7th ed. New York, NY: Springer; 2010.
9. Swisher SG, Hofstetter W, Wu TT, et al. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg 2005; 241: 810-817.
10. Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 2005; 103: 1347-1355.
11. Rizk NP, Venkatraman E, Bains MS, et al. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol 2007; 25: 507-512.
12. Law S, Kwong DL, Wong KH, et al. The effects of neoadjuvant chemoradiation on pTNM staging and its prognostic significance in esophageal cancer. J Gastrointest Surg 2006; 10: 1301-1311.
13. Barbour AP, Jones M, Gonen M, et al. Refining esophageal cancer staging after neoadjuvant therapy: Importance of treatment response. Ann Surg Oncol 2008; 15: 2894-2902.
14. Schneider PM, Baldus SE, Metzger R, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: Implications for response classification. Ann Surg 2005; 242: 684-692.
15. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73: 2680-2686.
16. Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: Final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 2001; 91: 2165-2174.
17. Stiles BM, Christos P, Port JL, et al. Predictors of survival in patients with persistent nodal metastases after preoperative chemotherapy for esophageal cancer. J Thorac Cardiovasc Surg 2010; 139: 387-394.
18. Mariette C, Piessen G, Briez N, et al. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg 2008; 247: 365-371.
19. Gu Y, Swisher SG, Ajani JA, et al. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer 2006; 106: 1017-1025.
20. Gaca JG, Petersen RP, Peterson BL, et al. Pathologic nodal status predicts disease-free survival after neoadjuvant chemoradiation for gastroesophageal junction carcinoma. Ann Surg Oncol 2006; 13: 340-346.
21. Akutsu Y, Shuto K, Kono T, et al. The number of pathologic lymph nodes involved is still a significant prognostic factor even after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma. J Surg Oncol 2012; 105: 756-760.
22. Reynolds JV, Muldoon C, Hollywood D, et al. Long-Term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg 2007; 245: 707-716.
23. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997; 337: 161-167.
24. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335: 462-467.
25. Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001; 19: 305-313.
26. Le Prise E, Etienne PL, Meunier B, et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 1994; 73: 1779-1178.
27. Kim MP, Correa AM, Lee J, et al. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: An orphan status. Ann Thorac Surg 2010; 90: 884-890.